A novel clinicogenetic prognostic score for follicular lymphoma.
暂无分享，去创建一个
[1] Robert Kridel,et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. , 2015, The Lancet. Oncology.
[2] A. K. Church,et al. BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma. , 2015, Blood.
[3] W. Hiddemann,et al. How we manage follicular lymphoma , 2014, Leukemia.
[4] Yan Liu,et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations , 2012, Nature.
[5] K. Tarte,et al. High rate of TNFRSF14 gene alterations related to 1p36 region in de novo follicular lymphoma and impact on prognosis , 2012, Leukemia.
[6] Ryan D. Morin,et al. Somatic mutation of EZH2 (Y641) in Follicular and Diffuse Large B-cell Lymphomas of Germinal Center Origin , 2010, Nature Genetics.
[7] Giovanni Martinelli,et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] P. Solal-Céligny. Follicular Lymphoma International Prognostic Index. , 2004, Current treatment options in oncology.